Supercharged immune cells take on Hard-to-Treat head and neck cancer
NCT ID NCT04139057
First seen Jan 28, 2026 · Last updated Jun 12, 2026 · Updated 22 times
Summary
This trial tested a new treatment for a type of head and neck cancer linked to the Epstein-Barr virus (EBV). The treatment uses specially engineered immune cells (TCR-T cells) that can recognize and attack the cancer, plus they release a substance to block a common cancer defense. The study involved 10 people with advanced cancer and aimed to find the safest dose. While promising, this is an early-stage trial, and more research is needed to know if it works as a long-term control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.